BR0015039A - Método para administrar um inibidor fosfodiesterase 4 - Google Patents

Método para administrar um inibidor fosfodiesterase 4

Info

Publication number
BR0015039A
BR0015039A BR0015039-8A BR0015039A BR0015039A BR 0015039 A BR0015039 A BR 0015039A BR 0015039 A BR0015039 A BR 0015039A BR 0015039 A BR0015039 A BR 0015039A
Authority
BR
Brazil
Prior art keywords
inhibitor
phosphodiesterase
administering
rate
administered
Prior art date
Application number
BR0015039-8A
Other languages
English (en)
Inventor
Robert D Murdoch
Theodore J Torphy
Barry D Zussman
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of BR0015039A publication Critical patent/BR0015039A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"MéTODO PARA ADMINISTRAR UM INIBIDOR FOSFODIESTERASE 4". Essa invenção se refere a um método de tratamento pra o aumento de dose de um inibidor PDE4 que pode ser administrado de uma vez e ser bem tolerado pelo paciente mediante a redução da taxa de absorção ou da taxa de elevação da concentração plasmática do inibidor.
BR0015039-8A 1999-10-29 2000-10-26 Método para administrar um inibidor fosfodiesterase 4 BR0015039A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16247799P 1999-10-29 1999-10-29
US16264199P 1999-11-01 1999-11-01
US17981700P 2000-02-02 2000-02-02
PCT/US2000/029453 WO2001032165A1 (en) 1999-10-29 2000-10-26 Method for administering a phosphodiesterase 4 inhibitor

Publications (1)

Publication Number Publication Date
BR0015039A true BR0015039A (pt) 2002-06-25

Family

ID=27388757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015039-8A BR0015039A (pt) 1999-10-29 2000-10-26 Método para administrar um inibidor fosfodiesterase 4

Country Status (29)

Country Link
US (1) US20030212112A1 (pt)
EP (1) EP1225884A4 (pt)
JP (1) JP2003513038A (pt)
KR (1) KR20020050249A (pt)
CN (1) CN1387433A (pt)
AP (1) AP2002002446A0 (pt)
AR (1) AR026254A1 (pt)
AU (1) AU772909B2 (pt)
BG (1) BG106623A (pt)
BR (1) BR0015039A (pt)
CA (1) CA2389293A1 (pt)
CO (1) CO5271676A1 (pt)
CZ (1) CZ20021443A3 (pt)
DZ (1) DZ3249A1 (pt)
EA (1) EA200200502A1 (pt)
HK (1) HK1049105A1 (pt)
HU (1) HUP0203682A3 (pt)
IL (1) IL148813A0 (pt)
MA (1) MA25562A1 (pt)
MX (1) MXPA02004220A (pt)
NO (1) NO20021937L (pt)
NZ (1) NZ518002A (pt)
OA (1) OA12078A (pt)
PE (1) PE20011004A1 (pt)
PL (1) PL355262A1 (pt)
SK (1) SK7292002A3 (pt)
TR (1) TR200201150T2 (pt)
UY (1) UY26422A1 (pt)
WO (1) WO2001032165A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
MXPA04011612A (es) * 2002-05-28 2005-03-07 Altana Pharma Ag Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
BRPI0406427B8 (pt) 2003-03-10 2021-05-25 Astrazeneca Ab processo para a preparação de roflumilast
WO2004096274A1 (ja) * 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. 気道内投与剤
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
DK1861074T3 (da) 2005-03-16 2013-07-29 Takeda Gmbh Smagsmaskeret doseringsform indeholdende roflumilast
EP2506711B1 (en) * 2009-12-03 2019-04-03 OPKO Health, Inc. Hypersulfated disaccharide formulations
PE20142318A1 (es) * 2011-12-27 2015-01-16 Celgene Corp Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
EP1225884A4 (en) 2005-06-15
AU1344501A (en) 2001-05-14
SK7292002A3 (en) 2002-12-03
AP2002002446A0 (en) 2002-03-31
CA2389293A1 (en) 2001-05-10
EA200200502A1 (ru) 2002-10-31
AR026254A1 (es) 2003-02-05
NZ518002A (en) 2004-01-30
WO2001032165A1 (en) 2001-05-10
DZ3249A1 (fr) 2001-05-10
MA25562A1 (fr) 2002-10-01
CZ20021443A3 (cs) 2003-01-15
PE20011004A1 (es) 2001-09-28
EP1225884A1 (en) 2002-07-31
NO20021937D0 (no) 2002-04-24
NO20021937L (no) 2002-05-30
MXPA02004220A (es) 2002-10-17
OA12078A (en) 2003-05-28
PL355262A1 (en) 2004-04-05
HK1049105A1 (zh) 2003-05-02
CN1387433A (zh) 2002-12-25
CO5271676A1 (es) 2003-04-30
HUP0203682A3 (en) 2003-10-28
AU772909B2 (en) 2004-05-13
HUP0203682A2 (hu) 2003-04-28
KR20020050249A (ko) 2002-06-26
TR200201150T2 (tr) 2002-09-23
IL148813A0 (en) 2002-09-12
JP2003513038A (ja) 2003-04-08
BG106623A (bg) 2003-02-28
UY26422A1 (es) 2001-07-31
US20030212112A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
BR0015039A (pt) Método para administrar um inibidor fosfodiesterase 4
BR0307975A (pt) Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
NO20051987L (no) Behandling av soppinfeksjoner.
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BR0314655A (pt) Droga de combinação
NO20014842D0 (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
ECSP034922A (es) Pirrolopirimidinas
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
AR052565A1 (es) Prevencion y tratamiento de trastornos tromboembolicos
RS52825B (en) PROCEDURES FOR THE TREATMENT OF DISORDERS OR DISEASES RELATED TO HYPERLIPIDEMIA AND HYPERHOLESTEROLEMIA WITH MINIMIZATION OF ADVERSE EFFECTS
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
BR0213293A (pt) Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
DK0624374T3 (da) Anvendelse af sulodexid og medicin, som indeholder dette, til behandlingen af diabetisk nephropati
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR0317095A (pt) Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease
ATE448788T1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.